FRTX Stock Price, Fresh Tracks Therapeutics Quote, Chart

Market Summary

USD0.93+0.03

Delayedas of 08 May 2024, 01:39 pm

3.33%

FRTX Alerts

1 major insider buys recently.

FRTX Stock Price

View Fullscreen

FRTX RSI Chart

FRTX Valuation

Market Cap

5.4M

Price/Earnings (Trailing)

-0.94

Price/Sales (Trailing)

0.67

Price/Free Cashflow

-1.24

FRTX Price/Sales (Trailing)

FRTX Profitability

Return on Equity

-57.34%

Return on Assets

-49.15%

Free Cashflow Yield

-80.79%

FRTX Fundamentals

FRTX Revenue

Revenue (TTM)

8.0M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

FRTX Earnings

Earnings (TTM)

-5.7M

Earnings Growth (Yr)

72.65%

Earnings Growth (Qtr)

-158.84%

Breaking Down FRTX Revenue

52 Week Range

0.93

(Low)(High)

Last 7 days

-1.1%

Last 30 days

-1.1%

Last 90 days

-9.1%

How does FRTX drawdown profile look like?

FRTX Financial Health

Current Ratio

6.98

FRTX Investor Care

Shares Dilution (1Y)

98.24%

Diluted EPS (TTM)

-1.24

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	7.2M	7.5M	7.7M	8.0M
2022	2.0M	3.7M	5.3M	6.9M
2021	1.5M	1.1M	758.5K	404.0K
2020	5.5M	3.5M	2.5M	1.8M
2019	9.4M	11.6M	9.7M	7.9M
2018	15.6M	12.6M	12.4M	10.9M
2017	13.1M	12.4M	13.0M	13.8M
2016	20.6M	20.6M	18.2M	14.5M
2015	17.7M	17.4M	19.0M	20.9M
2014	8.6M	11.6M	13.5M	15.2M
2013	7.6M	7.5M	6.9M	7.7M
2012	40.8M	41.6M	17.1M	17.5M
2011	7.9M	6.6M	31.0M	30.0M
2010	0	11.4M	10.0M	8.7M
2009	0	0	0	12.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Fresh Tracks Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 03, 2024	exploration capital, llc	bought	294	0.91	324	-
May 02, 2024	exploration capital, llc	bought	2,022	0.91	2,222	-
May 01, 2024	exploration capital, llc	bought	149,363	0.92	162,351	-
Apr 23, 2024	exploration capital, llc	bought	312	0.91	343	-
Apr 22, 2024	exploration capital, llc	bought	15,217	0.9	16,908	-
Apr 19, 2024	exploration capital, llc	bought	3,892	0.91	4,277	-
Apr 10, 2024	exploration capital, llc	bought	880	0.88	1,000	-
Apr 09, 2024	exploration capital, llc	bought	1,925	0.88	2,188	-
Apr 05, 2024	exploration capital, llc	bought	955	0.91	1,050	-
Apr 04, 2024	exploration capital, llc	bought	3,094	0.91	3,400	-

Which funds bought or sold FRTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	Blue Trust, Inc.	sold off	-100	-1,000	-	-%
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-22,368	-	-%
Feb 26, 2024	Virtu Financial LLC	sold off	-100	-42,000	-	-%
Feb 15, 2024	GTS SECURITIES LLC	sold off	-100	-48,597	-	-%
Feb 14, 2024	Skaana Management L.P.	unchanged	-	-	-	-%
Feb 14, 2024	Royal Bank of Canada	sold off	-100	-	-	-%
Feb 13, 2024	FMR LLC	sold off	-100	-13.00	-	-%
Feb 13, 2024	Tower Research Capital LLC (TRC)	sold off	-100	-9,917	-	-%
Feb 13, 2024	JBF Capital, Inc.	sold off	-100	-286,150	-	-%
Feb 13, 2024	BlackRock Inc.	sold off	-100	-4,646	-	-%

Are Funds Buying or Selling FRTX?

Are funds buying FRTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own FRTX

No. of Funds

FRTX Alerts

1 major insider buys recently.

Unveiling Fresh Tracks Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 18, 2024	exploration capital, llc	14.2%	850,000	SC 13G/A
Nov 28, 2023	exploration capital fund, lp	9.99%	597,000	SC 13G

Recent SEC filings of Fresh Tracks Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 03, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading
Apr 11, 2024	4	Insider Trading
Apr 05, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Mar 21, 2024	4	Insider Trading
Mar 18, 2024	15-12G	15-12G
Mar 15, 2024	10-K	Annual Report
Mar 13, 2024	4	Insider Trading
Mar 07, 2024	8-K	Current Report

Peers (Alternatives to Fresh Tracks Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.4B	6.8B	17.66%	-8.12%	-7.77	6.77	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.5B	2.0B	0.45%	-26.53%	-58.76	9.74	75.20%	68.82%
BMRN	15.7B	2.5B	-4.99%	-13.89%	76.35	6.35	13.74%	186.89%
INCY	12.2B	3.8B	-1.56%	-17.34%	16.38	3.24	8.58%	129.81%
MID-CAP
APLS	5.3B	524.1M	-21.34%	-51.87%	-12.77	10.17	394.93%	39.61%
BBIO	5.2B	107.9M	-1.17%	105.40%	-9.51	48.09	54.84%	-28.31%
AXSM	3.7B	251.0M	6.53%	-0.98%	-12.33	14.56	73.58%	-86.73%
ARWR	3.1B	240.7M	-3.03%	-38.20%	-10.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-4.16%	-19.91%	-46.38	3.91	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-0.20%	-12.84%	24.99	4.48	85.90%	-14.05%
NVAX	645.2M	983.7M	4.30%	-38.12%	-1.18	0.66	-50.36%	17.16%
CRBP	424.2M	881.7K	-0.70%	291.81%	-12.56	481.06	-77.61%	33.36%
INO	259.6M	4.9M	-5.85%	11.55%	-1.92	53.35	-54.97%	51.71%
IBIO	7.1M	2.1M	-3.32%	88.89%	-0.26	2.14	-13.45%	66.37%

Fresh Tracks Therapeutics Inc News

Latest updates

Fresh Tracks Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-100.0%	-	7,944	5,979	4,015	2,050	486	4,315	2,210	104	132	151	89.00	27.00	142	607	1,046	669	1,183	2,573	3,492	2,473
Costs and Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,001	5,258	4,075
Operating Expenses	-72.2%	1,652	5,947	2,417	4,350	6,643	6,562	5,773	9,499	6,409	13,491	11,729	9,019	7,428	4,492	5,733	5,145	11,510	7,238	5,552	8,085	1,862
S&GA Expenses	-69.1%	1,642	5,320	1,808	2,414	4,038	3,002	3,908	3,486	3,290	3,269	2,891	2,967	2,869	3,211	3,021	2,481	4,881	3,901	1,323	2,066	1,240
R&D Expenses	-98.4%	10.00	627	609	1,936	2,605	3,560	1,865	6,013	3,119	10,222	8,838	6,052	4,559	1,281	2,712	2,664	6,629	3,337	4,229	6,019	2,974
Interest Expenses	-	-	-	2.00	3.00	3.00	-	2.00	4.00	4.00	1.00	30.00	34.00	-	-	-	-	114	1,098	660	224	-
Net Income	-158.8%	-1,238	2,104	-2,284	-4,276	-4,527	-6,018	-1,147	-9,410	-6,067	-13,253	-11,149	-9,005	-7,365	-4,326	-5,119	-4,103	-10,862	-4,781	-3,654	-4,580	-3,670
Net Income Margin	38.7%	-0.71*	-1.16*	-2.29*	-2.22*	-3.04*	-4.27*	-8.13*	-19.56*	-97.71*	-53.75*	-28.61*	-17.59*	-11.48*	-	-	-	-	-	-	-	-
Free Cashflow	-136.5%	-1,124	3,081	-1,817	-4,486	-2,579	-4,249	-2,970	-9,541	-4,799	-11,146	-14,315	-5,892	-4,752	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-11.3%	12.00	13.00	10.00	12.00	10.00	14.00	19.00	21.00	30.00	24.00	29.00	39.00	34.00	26.00	27.00	13.00	18.00	31.00	43.00	46.00	9.00
Current Assets	-11.2%	12.00	13.00	10.00	12.00	10.00	14.00	18.00	21.00	30.00	24.00	29.00	39.00	34.00	26.00	27.00	13.00	18.00	31.00	43.00	46.00	8.00
Cash Equivalents	-9.3%	11.00	12.00	9.00	11.00	9.00	11.00	14.00	17.00	27.00	21.00	24.00	35.00	30.00	20.00	22.00	7.00	7.00	7.00	2.00	3.00	8.00
Net PPE	-22.7%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-	-	-	-	-	-	-	-	-	5.00	4.00	7.00	10.00	6.00	8.00	8.00	7.00	11.00	13.00	-	-	22.00
Current Liabilities	-21.4%	2.00	2.00	2.00	2.00	3.00	3.00	3.00	5.00	5.00	4.00	7.00	9.00	6.00	8.00	7.00	7.00	10.00	7.00	1.00	3.00	20.00
Shareholder's Equity	-9.3%	10.00	11.00	8.00	10.00	7.00	11.00	16.00	16.00	25.00	20.00	22.00	29.00	27.00	19.00	20.00	6.00	8.00	18.00	42.00	44.00	49.00
Retained Earnings	-0.7%	-172	-170	-173	-170	-166	-161	-155	-154	-145	-139	-126	-114	-105	-98.50	-94.20	-89.10	-84.98	-74.12	-449	-446	-71.62
Additional Paid-In Capital	0.1%	182	182	181	181	174	173	172	170	170	158	148	143	132	117	114	95.00	92.00	92.00	490	490	-
Shares Outstanding	0.8%	6.00	6.00	6.00	6.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00	1.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	4.00	-	-	-	15.00	-	-	-	66.00	-	-	-	27.00	-	-	-	19.00	-	-

Cashflow (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-136.5%	-1,124	3,082	-1,801	-4,500	-2,578	-4,248	-2,969	-9,540	-4,798	-11,145	-14,314	-5,891	-4,751	-3,993	-4,680	-6,610	-14,041	-12,438	-4,186	-5,316	-3,654
Share Based Compensation	-69.1%	267	863	410	379	490	539	576	551	596	777	421	469	584	553	453	403	525	324	299	384	195
Cashflow From Investing	-	-	-	-	-	-	-47.00	-	-	-	-	4.00	-40.00	-23.00	-	-	4,500	14,001	18,513	-2.00	-2.00	-4.00
Cashflow From Financing	-180.0%	-28.00	-10.00	-	6,569	8.00	1,065	160	-55.00	10,299	8,120	3,937	10,597	14,715	2,597	19,123	2,005	47.00	-929	2,998	520	-805

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

FRTX Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Total revenue	$ 8,006	$ 6,943
Operating expenses:
Research and development	3,182	14,043
General and administrative	11,184	14,434
Total operating expenses	14,366	28,477
Loss from operations	(6,360)	(21,534)
Other income	671	441
Interest expense	(5)	(9)
Net loss attributable to common stockholders	$ (5,694)	$ (21,102)
Net loss per common share attributable to common stockholders, basic (in usd per share)	$ (1.06)	$ (7.51)
Net loss per common share attributable to common stockholders, diluted (in usd per share)	$ (1.06)	$ (7.51)
Weighted-average shares used to compute net loss per common share attributable to common stockholders, basic (in shares)	5,394,551	2,808,075
Weighted-average shares used to compute net loss per common share attributable to common stockholders, diluted (in shares)	5,394,551	2,808,075
Contract revenue
Total revenue	$ 8,006	$ 6,851
Royalty revenue
Total revenue	$ 0	$ 92

FRTX Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 10,868	$ 8,680
Prepaid expenses and other current assets	684	1,403
Total current assets	11,552	10,083
Property and equipment, net	34	75
Contract asset, net of current portion	0	64
Operating lease right-of-use asset	0	49
Total assets	11,586	10,271
Current liabilities:
Accounts payable	406	571
Accrued liabilities	1,250	2,457
Lease liability	0	49
Total current liabilities	1,656	3,077
Commitments and contingencies (Note 5)
Stockholders’ equity:
Common stock, $0.01 par value, 300,000,000 shares authorized as of December 31, 2023 and 2022; 5,973,306 and 3,018,940 shares issued and outstanding as of December 31, 2023 and 2022, respectively	60	30
Additional paid-in capital	182,033	173,633
Accumulated deficit	(172,163)	(166,469)
Total stockholders’ equity	9,930	7,194
Total liabilities and stockholders’ equity	$ 11,586	$ 10,271

About Fresh Tracks Therapeutics Inc

Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops FRTX-02 (BBI-02), an oral DYRK1A inhibitor that is completed Phase 1 clinical trials for the treatment of autoimmune and inflammatory diseases; FRTX-10 (BBI-10), a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases; and FRTX-03, a topical DYRK1A inhibitor for the treatment of mild-to-moderate skin conditions, as well as next-generation kinase inhibitors. Fresh Tracks Therapeutics, Inc. has license and collaboration agreements with Carna Biosciences, Inc., and Voronoi Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

CEO	Mr. Andrew D. Sklawer
WEBSITE	frtx.com
INDUSTRY	Biotechnology
EMPLOYEES	13

Fresh Tracks Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Fresh Tracks Therapeutics Inc? What does FRTX stand for in stocks?

FRTX is the stock ticker symbol of Fresh Tracks Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Fresh Tracks Therapeutics Inc (FRTX)?

As of Tue May 07 2024, market cap of Fresh Tracks Therapeutics Inc is 5.38 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FRTX stock?

You can check FRTX's fair value in chart for subscribers.

What is the fair value of FRTX stock?

You can check FRTX's fair value in chart for subscribers. The fair value of Fresh Tracks Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Fresh Tracks Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FRTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Fresh Tracks Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether FRTX is over valued or under valued. Whether Fresh Tracks Therapeutics Inc is cheap or expensive depends on the assumptions which impact Fresh Tracks Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FRTX.

What is Fresh Tracks Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, FRTX's PE ratio (Price to Earnings) is -0.94 and Price to Sales (PS) ratio is 0.67. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FRTX PE ratio will change depending on the future growth rate expectations of investors.